Investing.com - Financial Markets Worldwide

H.C. Wainwright assumes coverage on Xeris Pharmaceuticals stock with Buy rating

Published 12/08/2025, 12:26
H.C. Wainwright assumes coverage on Xeris Pharmaceuticals stock with Buy rating
XERS
0.21%

Investing.com - H.C. Wainwright has assumed coverage on Xeris Pharmaceuticals (NASDAQ:XERS), currently trading at $7.20 with a market capitalization of $1.16 billion, with a Buy rating and a $10.00 price target, according to a research note released Tuesday. According to InvestingPro data, analyst targets range from $6.00 to $11.00.

The firm noted that Xeris stock has risen 108% year to date in 2025, significantly outperforming the XBI index, which is down 6.2% during the same period. InvestingPro data shows even more impressive gains, with a 220% return over the past year, though technical indicators suggest the stock is currently overbought.

H.C. Wainwright identified Recorlev as the most significant driver of near- and mid-term revenue growth for Xeris, highlighting the company’s goal of reaching $1 billion in revenue for this product by 2035.

The research firm indicated that current consensus estimates for Recorlev in the latter part of this decade do not align with the trajectory needed to reach management’s target, suggesting potential upside if Xeris continues its recent execution, particularly regarding new patient starts.

H.C. Wainwright also pointed to the company’s overall revenue goal of approximately $750 million by 2030 and the potential for XP-8121 in hypothyroidism, which could generate upwards of $1 billion in the long term.

In other recent news, Xeris Pharmaceuticals reported better-than-expected earnings for the second quarter of 2025. The company posted an earnings per share (EPS) of -0.01, surpassing the forecasted -0.03. Additionally, Xeris Pharmaceuticals achieved a revenue of $71.5 million, exceeding expectations by 11.85%. These recent developments highlight the company’s strong financial performance. The earnings announcement was followed by a notable surge in the company’s stock in pre-market trading, indicating strong investor confidence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.